Seagen prevails in patent infringement case against Daiichi Sankyo

US biotech Seagen (Nasdaq: SGEN) announced that a jury in the US District Court for the Eastern District of Texas found that Japanese pharma major Daiichi Sankyo (TYO: 4568) infringed Seagen’s US Patent No 10,808,039 by selling its cancer drug Enhertu (trastuzumab deruxtecan; DS-8201) in the USA.

Seagen, whose shares jumped almost 5% to $150.02 by close of trading in Friday, was awarded damages of $41.82 million for past infringement of the patent.

We are pleased that the jury recognized the validity of asserted claims of our patent and found that Daiichi Sankyo willfully infringed our proprietary technology without permission,” said Clay Siegall, president and chief executive of Seagen, adding: “As a pioneer and leader in antibody-drug conjugate (ADC) technology, protecting our intellectual property is essential to our ability to continue developing innovative therapies for cancer patients in need.”